Search
Pareto Securities' Healthcare Conference: Biotech Analyst Dan Akschuti shares his take on the the conference and the state of biotech, and highlights key companies to watch in the region
He sees an optimistic turn after a challenging couple of years. Plus, highlighting Vicore, Camurus, Oculis, and BioArctic. Coverage...
Sep 16, 2025
Leaders of Brandon Capital, a seed and VC firm formed in Australia and with an office in the UK as well, discuss their $290 million sixth fund
Founding Partner Stephen Thompson and Partner Jonathan Tobin list some of their recent investments, highlight the advantage of running...
Sep 12, 2025
Michael White, Head of Life Sciences & Healthcare, UK & Nordics at HSBC Innovation Banking, shares insights from his team's UK & Nordics: Life Sciences & Healthcare 1H 2025 Venture Financing Report
The report is full of data that shows where venture money is being invested in the region and by which investors, and includes these...
Sep 11, 2025
H.C. Wainwright & Co. CEO Mark Kaplan sees a warming up of the fundraising environment for biotech over the coming months
Kicking off BiotechTV's coverage of the 2025 HCW Global Investor Conference in New York, the new CEO of H.C. Wainwright gives his take on...
Sep 8, 2025
Stanford professor James Zou and his team created a virtual lab with AI scientists - they designed nanobodies for a COVID variant
Dr. Zou describes this work, which was published recently in Nature, and how the the AI scientists were able to do everything from debate...
Aug 26, 2025
William Blair Senior Biotech Analyst Andy Hsieh reacts to today's oral obesity data from Viking's VK2735 and recent data from Lilly's orforglipron
He shares his take on today's data, which saw Viking's stock decline by over 40%, and Lilly's earlier data which also sparked a Wall...
Aug 19, 2025
AI News: While most AI in healthcare is aimed at helping physicians better diagnose and treat disease, CureWise is built for patients to help understand their conditions and ask the right questions
Founder & CEO Steve Brown, who created CureWise after receiving his own diagnosis of a rare blood cancer, describes his journey and how...
Aug 7, 2025
As independent tenant advocates, Savills can help biotech and pharma companies make their real estate footprint align with their objectives and be more efficient
Austin Barrett, Vice Chairman and Head of Life Sciences, describes the type of work Savills does for clients today, including...
Jul 30, 2025
NYSE Strategist Eric Criscuolo shares his take on the markets and biotech sentiment
He discusses the importance of interest rates to high risk sectors like biotech, and comment on how our sector has not performed lately...
Jul 22, 2025
RBC's Healthcare Desk Strategist Chris McCarthy discusses biotech sentiment, and positioning around key events and catalysts that are upcoming
He highlights recent M&A, but also notes how the sector has not been reliant on deals like it has in the past. Plus, discussing how...
Jul 22, 2025
Jon Norris shares highlights from his 2025 Mid-Year Venture Healthcare Report
He discusses trends in deal size, therapeutic focus, IPOs, and more. DOWNLOAD THE FULL REPORT #sponsored
Jul 21, 2025
Southampton professor, and Curve Therapeutics' CSO, Ali Tavassoli describes the unique properties of cyclic peptides and why he believes Curve's cell-based method to drug discovery makes it different
He describes the properties that make cyclic peptides unique compared to small molecules and antibodies, and how Curve's approach is...
Jul 15, 2025
Jones Research analyst Catherine Novack discusses Capricor's regulatory roller coaster, RNA editing, and more
She gives a scenario analysis in the event that FDA asked Capricor for more data rather than approving the therapy by its August 31st...
Jun 27, 2025
Discussing hot button issues for biotech, and how they do or don't affect the mechanics of M&A, with one of the most experienced bankers in healthcare, Jefferies' Philip Ross
He describes how some front and center issues for biotech either do or don't affect the M&A environment such as China, negative enterprise values, the FTC, valuations, the patent cliff, and more.
Jun 27, 2025
William Blair biotech analyst Andy Hsieh takes stock of the obesity space after attending the 2025 American Diabetes Association's (ADA's) 85th Scientific Sessions in Chicago
He discusses data presented at #ADA25 including Eli Lillys Orforglipron and Bimagrumab, Novo Nordisk's CagriSema, and Amgen's MariTide....
Jun 26, 2025
The Co-Director of Cardiff University's Medicines Discovery Institute talks about the specialized work that happens here in neuroscience, cancer, and beyond
Simon Ward, Co-Director along with John Atack, describes the founding of the institue and why Cardiff University was a good fit. He...
Jun 20, 2025
SV Health Investors Managing Partner Kate Bingham shares the firm's investment philosophy and gives her take on the current state of life sciences in the United Kingdom and beyond
Kate Bingham describes the type of investments SV makes, which was in the news this week for being the founding investor of the...
Jun 20, 2025
BIO International 2025: Oppenheimer's Head of Healthcare Investment Banking, Michael Margolis, discusses biotech sentiment, M&A, and what it is like to raise money today
He describes how sentiment and the M&A environment have been improving, as well as some areas of the financing market. However, he...
Jun 17, 2025
BIO International 2025: Stifel's Tim Opler comments on improvements in sentiment he is seeing for the biotech sector, and his take on hot button issues
He explains how M&A and fundraising have been improving, and he describes what types of companies have been most appealing to investors....
Jun 16, 2025
BIO International 2025: An intro to the BIO International Convention, and stopping by the Korea Pavilion
From the floor of the 2025 BIO International Convention in Boston, Brad Loncar describes what this four-day conference is all about, and...
Jun 16, 2025
.png){kind=logo}